Literature DB >> 12441899

Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital.

Jorge Garbino1, Lenka Kolarova, Peter Rohner, Daniel Lew, Peter Pichna, Didier Pittet.   

Abstract

The incidence of fungal infections has been increasing for the last 3 decades, especially among neutropenic, cancer, and critically ill patients. These infections are associated with high mortality rates. We retrospectively reviewed medical charts of adult patients with fungemia from 1989 to 2000 at our institution. The characteristics of the population groups served by the hospital were described. Of 328 patients with fungemia, we reviewed 315 (96%) medical records, and focused on those with candidemia (n = 294). The species distribution in patients with candidemia showed that the most commonly identified species were Candida albicans (66%), followed by C. glabrata (17%), and C. parapsilosis (6%). The incidence of candidemia ranged from 0.2 to 0.46 per 10,000 patient-days with the highest incidence in 1993 and the lowest in 1997. Although most studies show an increased incidence of candidemia, we observed a reduction over the study period. Furthermore, we observed no shift from C. albicans to non-albicans Candida species despite a significant increase in the use of fluconazole. The overall mortality among patients with candidemia was 44%, with the highest rate in patients over 65 years (52%). Factors independently associated with higher mortality were patient age greater than 65 years, intensive care unit admission, and underlying cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12441899     DOI: 10.1097/00005792-200211000-00003

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  26 in total

Review 1.  Prophylaxis and treatment of invasive candidiasis in the intensive care setting.

Authors:  L Ostrosky-Zeichner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-10       Impact factor: 3.267

2.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

3.  Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003.

Authors:  Benito Almirante; Dolors Rodríguez; Benjamin J Park; Manuel Cuenca-Estrella; Ana M Planes; Manuel Almela; Jose Mensa; Ferran Sanchez; Josefina Ayats; Montserrat Gimenez; Pere Saballs; Scott K Fridkin; Juliette Morgan; Juan L Rodriguez-Tudela; David W Warnock; Albert Pahissa
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

Review 4.  Epidemiology, incidence and risk factors for invasive candidiasis in high-risk patients.

Authors:  Ercole Concia; Anna Maria Azzini; Michela Conti
Journal:  Drugs       Date:  2009       Impact factor: 9.546

5.  Micafungin at physiological serum concentrations shows antifungal activity against Candida albicans and Candida parapsilosis biofilms.

Authors:  M Guembe; J Guinea; L J Marcos-Zambrano; A Fernández-Cruz; T Peláez; P Muñoz; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

6.  Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers.

Authors:  Arnaldo L Colombo; Marcio Nucci; Benjamin J Park; Simone A Nouér; Beth Arthington-Skaggs; Daniel A da Matta; David Warnock; Juliette Morgan
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

Review 7.  Critical issues in the clinical management of complicated intra-abdominal infections.

Authors:  Stijn Blot; Jan J De Waele
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program.

Authors:  Rana A Hajjeh; Andre N Sofair; Lee H Harrison; G Marshall Lyon; Beth A Arthington-Skaggs; Sara A Mirza; Maureen Phelan; Juliette Morgan; Wendy Lee-Yang; Meral A Ciblak; Lynette E Benjamin; Laurie Thomson Sanza; Sharon Huie; Siew Fah Yeo; Mary E Brandt; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

Review 9.  Management of invasive candidiasis in critically ill patients.

Authors:  Stijn Blot; Koenraad Vandewoude
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation.

Authors:  Marya D Zilberberg; Smita Kothari; Andrew F Shorr
Journal:  Crit Care       Date:  2009-06-19       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.